What’s the current market cap for Tandem Diabetes Care stock?

Tandem Diabetes Care (TNDM) has a market cap of $996M as of May 27, 2026.

What is the P/E ratio for Tandem Diabetes Care stock?

The price to earnings (P/E) ratio for Tandem Diabetes Care (TNDM) stock is 0 as of May 27, 2026.

Does Tandem Diabetes Care stock pay dividends?

No, Tandem Diabetes Care (TNDM) stock does not pay dividends to its shareholders as of May 27, 2026.

When is the next Tandem Diabetes Care dividend payment date?

Tandem Diabetes Care (TNDM) stock does not pay dividends to its shareholders.

What is the beta indicator for Tandem Diabetes Care?

Tandem Diabetes Care (TNDM) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Tandem Diabetes Care stock | $TNDM Share Price

13:30

15:10

16:45

18:25

20:00

About Tandem Diabetes Care

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Ticker

$TNDM

Sector

Health

Primary listing

NASDAQ

Employees

2,500

Headquarters

San Diego, United States

Website

www.tandemdiabetes.com

TNDM Metrics

BasicAdvanced

$996m

-$1.39

1.64

What the Analysts think about TNDM

Analyst ratings (Buy, Hold, Sell) for Tandem Diabetes Care stock.

Bulls say / Bears say

Tandem posted record first-quarter 2026 revenue of $247 million, surpassing the consensus estimate of $242.08 million by over 2% and reflecting 5.5% year-over-year growth, highlighting sustained revenue momentum. (Reuters)

The company’s gross margin rose to 55% in Q1 2026, up 480 basis points from Q1 2025, supported by scaling manufacturing, a favorable product mix, and more efficient supply economics. (Reuters)

In late April 2026, the US FDA approved Tandem’s Control-IQ+ automated insulin delivery technology for use in pregnancies affected by type 1 diabetes, making Tandem the first and only company with such an indication and significantly expanding its total addressable market. (Reuters)

Tandem’s transition to a pay-as-you-go pharmacy model is projected to create $85 million to $95 million in revenue headwinds for 2026, which could dampen near-term sales growth. (Reuters)

Proposed changes to the Medicare Competitive Bidding Program by CMS could allow more competitive switching and reduce the five-year contract lock-in, which led to a 9.6% drop in TNDM shares and highlights reimbursement risks. (Reuters)

Barclays cautions that growing competition in the automated insulin delivery segment from 2026—including Medtronic’s upcoming Fit patch pump and increased offerings from Abbott and Insulet—may put pressure on Tandem’s market share and valuation multiples. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.

TNDM Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

TNDM Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TNDM

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

The company’s gross margin rose to 55% in Q1 2026, up 480 basis points from Q1 2025, supported by scaling manufacturing, a favorable product mix, and more efficient supply economics. (Reuters)

Tandem’s transition to a pay-as-you-go pharmacy model is projected to create $85 million to $95 million in revenue headwinds for 2026, which could dampen near-term sales growth. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.